Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Goebell

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Urologia Internationalis|February 4, 2024
Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature ReviewAnnemarie Uhlig, Lothar Bergmann, Martin Bögemann, et al.
Current Oncology Reports|May 9, 2025
Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable PrognosisRicky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, et al.
Current Oncology Reports|November 20, 2024
Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable PrognosisRicky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, et al.
Urologia Internationalis|February 20, 2025
Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)Bernd J Schmitz-Dräger, Ekkehardt Bismarck, Thomas Ebert, et al.
Der Urologe. Ausg. A|May 28, 2021
[What do urologist do in daily practice? : A first "unfiltered" look at patient care]Peter J Goebell, Sulafah El-Khadra, Marcus Horstmann, et al.
BMC Cancer|March 22, 2014
Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective studyAnja Rogler, Sabine Hoja, Johannes Giedl, et al.
BMC Cancer|May 1, 2015
Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional studyLothar Bergmann, Ulrich Kube, Christian Doehn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Concepts for banking tissue in urologic oncology--the International Bladder Cancer BankPeter J Goebell, Susan Groshen, Bernd J Schmitz-Dräger, et al.
Future Oncology (London, England)|September 23, 2020
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinomaPeter J Goebell, Philipp Ivanyi, Jens Bedke, et al.
The Journal of Pathology|June 29, 2004
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancerSunanda J Chatterjee, Ben George, Peter J Goebell, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Urologia Internationalis|February 4, 2024
Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature ReviewAnnemarie Uhlig, Lothar Bergmann, Martin Bögemann, et al.
Current Oncology Reports|May 9, 2025
Correction to: Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable PrognosisRicky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, et al.
Current Oncology Reports|November 20, 2024
Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable PrognosisRicky Frazer, José Ángel Arranz, Sergio Vázquez Estévez, et al.
Urologia Internationalis|February 20, 2025
Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)Bernd J Schmitz-Dräger, Ekkehardt Bismarck, Thomas Ebert, et al.
Der Urologe. Ausg. A|May 28, 2021
[What do urologist do in daily practice? : A first "unfiltered" look at patient care]Peter J Goebell, Sulafah El-Khadra, Marcus Horstmann, et al.
BMC Cancer|March 22, 2014
Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective studyAnja Rogler, Sabine Hoja, Johannes Giedl, et al.
BMC Cancer|May 1, 2015
Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional studyLothar Bergmann, Ulrich Kube, Christian Doehn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Concepts for banking tissue in urologic oncology--the International Bladder Cancer BankPeter J Goebell, Susan Groshen, Bernd J Schmitz-Dräger, et al.
Future Oncology (London, England)|September 23, 2020
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinomaPeter J Goebell, Philipp Ivanyi, Jens Bedke, et al.
The Journal of Pathology|June 29, 2004
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancerSunanda J Chatterjee, Ben George, Peter J Goebell, et al.
Pageof 11